Prakt. lékáren. 2021; 17(3): e03-e14 | DOI: 10.36290/lek.2021.040

Treatment of multiple sclerosis from the pharmacist´s perspective

Miroslav Turjap, Olga Nedopílková
Oddělení klinické farmacie, lékárna FN Ostrava

Multiple sclerosis (MS) is an autoimmune chronic progressive inflammatory disease of the CNS that results in irreversible damage to axons and myelin with atrophy of the brain and spinal cord, resulting in gradual disability. The treatment of patients suffering from MS in the Czech Republic is concentrated in 15 highly specialized MS centres. MS is treatable in most patients, and timely treatment can delay disease progression and improve patients' quality of life. Pharmacotherapy is an essential modality in the treatment of MS. This article provides brief information on the treatment of multiple sclerosis from the pharmacist´s perspective. More space is dedicated to disease-modifying drugs.

Keywords: multiple sclerosis, disease-modifying drugs, symptomatic treatment, pharmacovigilance.

Published: October 12, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Turjap M, Nedopílková O. Treatment of multiple sclerosis from the pharmacist´s perspective. Praktické lékárenství. 2021;17(3):e03-14. doi: 10.36290/lek.2021.040.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lassmann H, van Horssen J. The molecular basis of neurodegeneration in multiple sclerosis. FEBS letters 2011; 585(23): 3715-3723. Go to original source... Go to PubMed...
    2. Degelman ML, Herman KM. Smoking and multiple sclerosis: A systematic review and meta-analysis using the Bradford Hill criteria for causation. Multiple sclerosis and related disorders 2017; 17: 207-216. Go to original source... Go to PubMed...
    3. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296(23): 2832-2838. Go to original source... Go to PubMed...
    4. Mokry LE, Ross S, Ahmad OS, et al. Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLoS medicine 2015; 12(8): e1001866. Go to original source... Go to PubMed...
    5. Kubala Havrdová E. Klinický doporučený postup pro diagnostiku a léčbu roztroušené sklerózy a neuromyelitis optica a onemocnění jejího širšího spektra. Dostupný z: https://www.czech-neuro.cz/pro-odborniky/doporucene-postupy/klinicke-standardy/ klinicky-doporuceny-postup-pro-diagnostiku-a-lecbu-roztrousene-sklerozy-a-neuromyelitis-optica-a-onemocneni-jejiho-sirsiho-spektra/. Publikováno 27. 4. 2020. (přístup 14. 3. 2021)
    6. Štětkářová I, Medová E, Havrdová E. Roztroušená skleróza a jiná demyelinizační onemocnění. In: Štětkářová I, ed. Moderní farmakoterapie v neurologii. 2 ed. Praha: Maxdorf Jessenius; 2017: 149-169.
    7. Cocco E, Marrosu MG. The current role of mitoxantrone in the treatment of multiple sclerosis. Expert review of neurotherapeutics 2014; 14(6): 607-616. Go to original source... Go to PubMed...
    8. Wolinsky JS, Arnold DL, Brochet B, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. The Lancet Neurology 2020; 19(12): 998-1009. Go to original source... Go to PubMed...
    9. Olek M, Mowry E. Treatment of primary progressive multiple sclerosis in adults. In: UpToDate Online, Waltham, MA.2020. (přístup 14. 3. 2021)
    10. Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391(10127): 1263-1273. Go to original source... Go to PubMed...
    11. Ostkamp P, Salmen A, Pignolet B, et al. Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proceedings of the National Academy of Sciences 2021; 118(1). Go to original source... Go to PubMed...
    12. Goodman AD, Brown TR, Edwards KR, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68(4): 494-502. Go to original source... Go to PubMed...
    13. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine 2018; 49: 12-19. Go to original source... Go to PubMed...
    14. Torres-Moreno MC, Papaseit E, Torrens M, et al. Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis. JAMA Network Open 2018; 1(6): e183485-e183485. Go to original source... Go to PubMed...
    15. Rice J, Cameron M. Cannabinoids for Treatment of MS Symptoms: State of the Evidence. Curr Neurol Neurosci Rep 2018; 18(8): 50. Go to original source... Go to PubMed...
    16. SÚKL. SPC Tecfidera. https://www.ema.europa.eu/en/documents/product-information/tecfidera-epar-product-information_cs.pdf (přístup 14. 3. 2021).
    17. SÚKL. SPC Gilenya. https://www.ema.europa.eu/en/documents/product-information/gilenya-epar-product-information_cs.pdf (přístup 14. 3. 2021).
    18. SÚKL. SPC Mavenclad. https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_cs.pdf (přístup 14. 3. 2021).
    19. SÚKL. SPC Mayzent. https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_cs.pdf (přístup 14. 3. 2021).
    20. SÚKL. SPC Aubagio. https://www.ema.europa.eu/en/documents/product-information/aubagio-epar-product-information_cs.pdf (přístup 14. 3. 2021).
    21. SÚKL. SPC Avonex. https://www.ema.europa.eu/en/documents/product-information/avonex-epar-product-information_cs.pdf (přístup 14. 3. 2021).
    22. SÚKL. SPC Rebif. https://www.ema.europa.eu/en/documents/product-information/rebif-epar-product-information_cs.pdf (přístup 14. 3. 2021).
    23. SÚKL. SPC Betaferon. https://www.ema.europa.eu/en/documents/product-information/betaferon-epar-product-information_cs.pdf (přístup 14. 3. 2021).
    24. SÚKL. SPC Plegridy. https://www.ema.europa.eu/en/documents/product-information/plegridy-epar-product-information_cs.pdf (přístup 14. 3. 2021).
    25. SÚKL. SPC Copaxone. https://www.sukl.cz/modules/medication/download.php?file=SPC162779.pdf&type=spc&as=copaxone-spc (přístup 14. 3. 2021).
    26. SÚKL. SPC Lemtrada. https://www.ema.europa.eu/en/documents/product-information/lemtrada-epar-product-information_cs.pdf (přístup 14. 3. 2021).
    27. SÚKL. SPC Tysabri. https://www.ema.europa.eu/en/documents/product-information/tysabri-epar-product-information_cs.pdf (přístup 14. 3. 2021).
    28. SÚKL. SPC Ocrevus. https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information_cs.pdf (přístup 14. 3. 2021).15. Rice J, Cameron M. Cannabinoids for Treatment of MS Symptoms: State of the Evidence. Curr Neurol Neurosci Rep 2018; 18(8): 50. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.